AnteoTech Signs Australian Distribution Agreement for EuGeni ...

AnteoTech Signs Australian Distribution Agreement for EuGeni  AnteoTech secures EuGeni Distribution Agreement with Abacus dx and its New Zealand operating company.  Abacus dx to become exclusive distributor in Australia, New Zealand and Pacific Islands.  Agreement comes into effect beginning Q4 2021 to align with anticipated TGA registration. AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to advise that it has signed a Distribution Agreement (Agreement) with Abacus dx Pty Ltd (Abacus) for the distribution of the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT)1. In anticipation of Therapeutic Goods Administration (TGA) registration in Q4, AnteoTech will commence distributor training and business development activities with Abacus as the companies work towards building a customer base in the public and private healthcare and screening markets. With the assistance of AnteoTech, Abacus will be taking the lead on domestic direct marketing activities.